Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIV-509 versus placebo in adults with moderate to severe atopic dermatitis
2025-522113-35-00Phase 2Authorised
- Sponsor
- Triveni Bio
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing TRIV-509 with Placebo (2 arms). Primary endpoint: Percentage of participants with improvement of atopic dermatitis at Week 16. Planned start Jan 2026; status: authorised.
02
Drugs
TRIV-509
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-522113-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522113-35-00.